Mirati Therapeutics, Inc.
MRTX
Rang în acțiuni
#4928
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Preț acțiune
$58.70
Ultima sincronizare: 2024-01-23
Capitalizare de piață
$2.98B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Mirati Therapeutics, Inc. (MRTX)
Categorie
Healthcare
EPS pentru Mirati Therapeutics, Inc. (MRTX)
EPS la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Mirati Therapeutics, Inc., EPS-ul actual al companiei (TTM) este 0. La sfârșitul anului 2026, compania avea un EPS de 0 egal cu EPS-ului din 2026, care a fost de 0.
Istoricul EPS pentru Mirati Therapeutics, Inc. din 2026 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | ||
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
